The Department of Health and Human Services recently distributed 27,000 portable COVID-19 molecular test kits, which Alaska, Florida, Louisiana, New Jersey, and Texas can use at the point of care to verify antigen test results within 20 minutes. The pilot program is part of a $481 million contract with Cue Health that HHS and the Department of Defense announced last month. The Food and Drug Administration in June authorized the testing system’s emergency use in patient care settings operating under a CLIA certificate of waiver, compliance or accreditation. “The pilot program will help us determine how well the Cue test will be adapted in institutions and communities,” said HHS Assistant Secretary for Health Brett Giroir, M.D.

Related News Articles

Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…